IL148044A0 - Process to make a sustained release formulation - Google Patents

Process to make a sustained release formulation

Info

Publication number
IL148044A0
IL148044A0 IL14804400A IL14804400A IL148044A0 IL 148044 A0 IL148044 A0 IL 148044A0 IL 14804400 A IL14804400 A IL 14804400A IL 14804400 A IL14804400 A IL 14804400A IL 148044 A0 IL148044 A0 IL 148044A0
Authority
IL
Israel
Prior art keywords
make
sustained release
release formulation
formulation
sustained
Prior art date
Application number
IL14804400A
Other languages
English (en)
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Publication of IL148044A0 publication Critical patent/IL148044A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
IL14804400A 1999-08-18 2000-08-14 Process to make a sustained release formulation IL148044A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE19990700A IES990700A2 (en) 1999-08-18 1999-08-18 Process to make a sustained release formulation
PCT/IE2000/000099 WO2001012232A2 (en) 1999-08-18 2000-08-14 Process to make a sustained release formulation

Publications (1)

Publication Number Publication Date
IL148044A0 true IL148044A0 (en) 2002-09-12

Family

ID=11042112

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14804400A IL148044A0 (en) 1999-08-18 2000-08-14 Process to make a sustained release formulation

Country Status (25)

Country Link
US (1) US6893645B1 (pl)
EP (1) EP1212095B1 (pl)
JP (1) JP3730917B2 (pl)
CN (2) CN1823736A (pl)
AR (1) AR022647A1 (pl)
AT (1) ATE243044T1 (pl)
AU (1) AU755229B2 (pl)
BR (1) BR0013349A (pl)
CA (1) CA2380902C (pl)
CZ (1) CZ294433B6 (pl)
DE (1) DE60003438T2 (pl)
DK (1) DK1212095T3 (pl)
ES (1) ES2195925T3 (pl)
HU (1) HUP0202895A3 (pl)
IE (1) IES990700A2 (pl)
IL (1) IL148044A0 (pl)
MX (1) MXPA02001415A (pl)
NO (1) NO20020762L (pl)
NZ (1) NZ517251A (pl)
PL (1) PL199862B1 (pl)
PT (1) PT1212095E (pl)
RU (1) RU2211694C1 (pl)
TW (1) TWI230069B (pl)
WO (1) WO2001012232A2 (pl)
ZA (1) ZA200202027B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767837B2 (en) * 1999-08-18 2003-11-27 Ipsen Pharma S.A.S. Sustained release formulation of a peptide
EP1348444B1 (en) * 1999-08-18 2006-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Sustained release formulation of a peptide complexed with a polymer
US7109166B1 (en) 1999-08-18 2006-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Sustained release formulation of a peptide
EP1697035B1 (en) * 2003-12-22 2017-11-15 Warren H. Finlay Powder formation by atmospheric spray-freeze drying
MX2007004676A (es) 2004-10-27 2007-11-14 Univ Denver Analogos de la hormona adrenocorticotropica y metodos relacionados.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
DK0678018T3 (da) 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5863985A (en) * 1995-06-29 1999-01-26 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
RO117259B1 (ro) * 1993-08-09 2001-12-28 Biomeasure Inc. Derivaţi peptidici, terapeutici
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
WO1998008528A1 (en) * 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
DE69907870T2 (de) 1998-01-29 2004-03-04 Kinerton Ltd., Blanchardstown Verfahren zur herstellung von absorbierbaren mikropartikeln
CN1278195A (zh) 1998-08-28 2000-12-27 三丰株式会社 被测定工件的自动清洗装置及设有该装置的自动生产系统
AU767837B2 (en) * 1999-08-18 2003-11-27 Ipsen Pharma S.A.S. Sustained release formulation of a peptide

Also Published As

Publication number Publication date
ZA200202027B (en) 2002-12-24
WO2001012232A3 (en) 2002-04-04
DK1212095T3 (da) 2003-10-06
WO2001012232A2 (en) 2001-02-22
EP1212095B1 (en) 2003-06-18
CA2380902C (en) 2008-08-05
BR0013349A (pt) 2002-04-23
CN1246040C (zh) 2006-03-22
AR022647A1 (es) 2002-09-04
WO2001012232A8 (en) 2002-06-06
HK1044285A1 (en) 2002-10-18
PL354263A1 (pl) 2003-12-29
NO20020762L (no) 2002-04-16
EP1212095A2 (en) 2002-06-12
PT1212095E (pt) 2003-10-31
NZ517251A (en) 2003-08-29
US6893645B1 (en) 2005-05-17
ES2195925T3 (es) 2003-12-16
AU6464700A (en) 2001-03-13
ATE243044T1 (de) 2003-07-15
CA2380902A1 (en) 2001-02-22
AU755229B2 (en) 2002-12-05
HUP0202895A2 (hu) 2003-02-28
CZ2002266A3 (cs) 2002-05-15
JP2003507346A (ja) 2003-02-25
MXPA02001415A (es) 2002-08-12
RU2211694C1 (ru) 2003-09-10
RU2002106809A (ru) 2004-01-20
DE60003438D1 (de) 2003-07-24
HUP0202895A3 (en) 2003-11-28
CZ294433B6 (cs) 2005-01-12
DE60003438T2 (de) 2004-05-06
PL199862B1 (pl) 2008-11-28
TWI230069B (en) 2005-04-01
JP3730917B2 (ja) 2006-01-05
CN1823736A (zh) 2006-08-30
CN1377283A (zh) 2002-10-30
IES990700A2 (en) 2001-08-22
NO20020762D0 (no) 2002-02-15

Similar Documents

Publication Publication Date Title
PL354120A1 (pl) Preparat peptydu o przedłużonym uwalnianiuPreparat peptydu o przedłużonym uwalnianiu
GB9901349D0 (en) A process
GB2360990B (en) Soap wrappers
IL148044A0 (en) Process to make a sustained release formulation
AU7887400A (en) A slow release pharmaceutical composition
GB9918087D0 (en) Detergent tablets
GB9925417D0 (en) Improvements relating to screenboxes
SI1212095T1 (en) Process to make a sustained release formulation
GB9902557D0 (en) Improvements to improve a danbouy
SG87119A1 (en) A method to form uniform silicide features
GB0021992D0 (en) A fur remover
EP1236736A4 (en) 2-AMINOPURINDERIVATE
GB9923682D0 (en) Improvements relating to security-pushout prevention
AU2950900A (en) Arrangement related to a call procedure
GB9916754D0 (en) A composition
GB9924080D0 (en) Improvements relating to fasteners
IL132832A0 (en) A technique to produce fullerenes
SI1149089T1 (en) PROCESS TO PREPARE TETRAHYDROTHIOPYRAN-o-FLUORINATED CARBAMATES
GB9926227D0 (en) Garments designed to adhere to similar garments
TW435423U (en) Pacifier used as a decoration
GB2345464B (en) Improvements relating to forms
GB9923835D0 (en) A oval facecloth mated to a sponge
GB9903159D0 (en) Improvements relating to window-walls
GB9929121D0 (en) Improvements relating to buckles
GB9902568D0 (en) Improvements relating to buckles

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees